Department of Justice Investigation of the Orthopaedic Industry

1. High-Yield Summary

• The Landmark 2007 Federal Settlement: In September 2007, the United States Department of Justice (DOJ) and the US Attorney’s Office for the District of New Jersey concluded an industry-wide criminal and civil investigation into the five major orthopaedic joint reconstruction manufacturers: Zimmer, DePuy Orthopaedics, Biomet, Smith & Nephew, and Stryker Orthopaedics. These manufacturers controlled approximately 95% of the United States hip and knee implant market.
• Core Statutory Allegations: The federal investigation alleged systematic violations of the federal Anti-Kickback Statute (AKS; 42 U.S.C. § 1320a-7b(b)) and the civil False Claims Act (FCA; 31 U.S.C. § 3729). The government asserted that manufacturers used non-bona fide consulting agreements, lavish advisory boards, unrestricted travel, intellectual property royalties, and research grants as unlawful financial inducements to orthopaedic surgeons to select and maintain proprietary implant volume.
• Financial Recovery and Corporate Restructuring: Four manufacturers (Zimmer, DePuy, Biomet, and Smith & Nephew) paid a combined $311 million in civil False Claims Act settlements, entered into 18-month Deferred Prosecution Agreements (DPAs) with appointed federal monitors, and executed 5-year Corporate Integrity Agreements (CIAs) with the Department of Health and Human Services Office of Inspector General (HHS-OIG). Stryker Orthopaedics executed a Non-Prosecution Agreement (NPA) without financial penalties due to voluntary early cooperation.
• The Birth of Modern Public Disclosure: The DPAs mandated public website disclosure of all financial disbursements to physician consultants, setting the direct legislative precedent for Section 6002 of the 2010 Patient Protection and Affordable Care Act (the Physician Payments Sunshine Act) and the establishment of the CMS Open Payments Database.
• Transformation of Surgeon-Industry Collaboration: The investigation established rigid legal boundaries distinguishing bona fide clinical innovation, genuine patent royalties, and fair market value (FMV) consulting from unlawful volume-based marketing incentives. It compelled the adoption of the American Academy of Orthopaedic Surgeons (AAOS) Standards of Professionalism on Orthopaedist-Industry Relations and catalyzed hospital value analysis committees (VACs).

2. Historical Background & Genesis of the Investigation

The modern era of total joint arthroplasty developed through intense collaboration between academic orthopaedic surgeons, clinical investigators, and biomedical device engineers. In the 1980s and 1990s, surgeon-industry partnerships yielded transformative clinical breakthroughs, including cementless porous ingrowth coatings, modular femoral components, modern bearing tribology, and specialized instrumentation. However, as the joint replacement market matured into a multi-billion-dollar commercial sector, competition among manufacturers intensified.

Market Concentration in Joint Arthroplasty

By 2005, the United States reconstructive joint market exhibited extreme commercial consolidation. Five corporate entities (Zimmer Holdings, DePuy Orthopaedics [Johnson & Johnson], Biomet, Smith & Nephew, and Stryker Orthopaedics) controlled roughly 95% of total hip and total knee arthroplasty component sales nationwide. Because implants were selected directly by attending surgeons rather than hospitals or purchasing departments, manufacturers focused commercial resources on securing physician allegiance.

Whistleblower Allegations and Federal Subpoenas

In 2002, the US Attorney’s Office for the District of New Jersey initiated an inquiry following qui tam whistleblower complaints filed under the False Claims Act. Federal prosecutors issued subpoenas to the top manufacturers in March 2005, requesting detailed financial accounting of all consulting contracts, designer agreements, product development royalties, CME sponsorships, and research funding provided to orthopaedic surgeons between 2002 and 2006. The inquiry focused on whether financial arrangements were genuine fair-market compensation for professional services rendered, or disguised kickbacks designed to induce surgeons to implant specific devices in Medicare and Medicaid beneficiaries.

3. Statutory & Regulatory Framework

Federal prosecution of medical device manufacturer relationships rests upon a triad of overlapping federal healthcare fraud and abuse statutes. An understanding of these statutory mechanisms is essential for all practicing orthopaedic surgeons.

Federal Anti-Kickback Statute (AKS)

The Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)) is a criminal statute prohibiting the knowing and willful solicitation, receipt, offer, or payment of any remuneration (including kickbacks, bribes, rebates, lavish gifts, or above-market consulting fees) directly or indirectly, in cash or in kind, to induce or reward patient referrals or the purchase, lease, order, or recommendation of any item or service payable under federal healthcare programs (such as Medicare and Medicaid). The statute establishes felony criminal liability, punishable by substantial fines, mandatory exclusion from federal healthcare programs, and imprisonment up to ten years.

Crucially, federal judicial precedent enforces the “One Purpose Rule”: if even one purpose of the remuneration is to induce or reward device utilization or program referrals, the arrangement violates the statute, even if other legitimate clinical or educational purposes coexist.

Civil False Claims Act (FCA)

The False Claims Act (31 U.S.C. § 3729) imposes civil liability on any individual or entity that knowingly presents, or causes to be presented, a false or fraudulent claim for payment to the federal government. Following statutory amendments, claims resulting from an underlying violation of the Anti-Kickback Statute automatically constitute false claims under the FCA. The FCA provides for treble damages (three times the actual financial loss incurred by the government) plus mandatory statutory per-claim civil penalties.

Physician Self-Referral Law (Stark Law) Comparison

The Ethics in Patient Referrals Act (42 U.S.C. § 1395nn), commonly known as the Stark Law, is a strict-liability civil statute prohibiting physicians from referring Medicare or Medicaid patients for designated health services (DHS) to an entity with which the physician (or an immediate family member) possesses a financial relationship, unless a statutory exception applies. While the Anti-Kickback Statute requires proof of intent (scienter) and applies across all healthcare services and referral sources, the Stark Law requires no intent and governs specific physician ownership and compensation arrangements.

Statutory Authority	Legal Classification	Core Prohibition	Intent Requirement (Scienter)	Statutory Safe Harbors / Exceptions	Penalties & Enforcement
Anti-Kickback Statute (AKS) 42 U.S.C. § 1320a-7b(b)	Criminal & Civil	Offering, paying, soliciting, or receiving remuneration to induce referrals or device purchases payable under federal healthcare programs.	Knowing and willful conduct (“One Purpose Rule”).	Personal services and management contracts safe harbor; bona fide employment safe harbor.	Felony conviction, up to 10 years imprisonment, $100,000 criminal fine per violation, civil monetary penalties, and program exclusion.
False Claims Act (FCA) 31 U.S.C. § 3729	Civil (with parallel criminal provisions)	Knowingly submitting, or causing submission of, false or fraudulent claims for federal reimbursement; tainted claims derived from AKS violations.	Knowledge, deliberate ignorance, or reckless disregard; no proof of specific intent to defraud required.	No statutory safe harbors; affirmative defense of government knowledge or objective good faith.	Treble damages (3x government losses) plus mandatory statutory inflation-adjusted penalties per fraudulent claim.
Stark Law 42 U.S.C. § 1395nn	Civil (Strict Liability)	Physician referrals of Medicare/Medicaid patients for Designated Health Services (DHS) to entities with which the physician has a financial relationship.	Strict liability (zero proof of intent or knowledge required).	Bona fide employment exception, fair market value compensation exception, in-office ancillary services exception.	Denial of payment, mandatory refund of collected funds, civil penalties up to $15,000 per billable service, and program exclusion.

4. The 2007 Settlements & Resolution Terms

On September 27, 2007, the Department of Justice announced comprehensive settlement agreements resolving the criminal and civil investigations into the five reconstructive implant manufacturers.

Corporate Financial Penalties ($311 Million Breakdown)

Four manufacturers entered into civil settlement agreements under the False Claims Act, committing to pay a combined $311 million to the federal government and participating state Medicaid programs:

• Zimmer Inc.: Paid $169.5 million in civil restitution.
• DePuy Orthopaedics Inc.: Paid $84.7 million in civil restitution.
• Smith & Nephew Inc.: Paid $28.9 million in civil restitution.
• Biomet Inc.: Paid $26.9 million in civil restitution.
• Stryker Orthopaedics: Paid zero financial settlement due to early self-disclosure and complete voluntary cooperation throughout the investigation.

Deferred Prosecution Agreements (DPAs) vs. Non-Prosecution Agreements (NPAs)

In parallel with the civil False Claims Act recoveries, the United States Attorney’s Office filed federal criminal complaints against Zimmer, DePuy, Biomet, and Smith & Nephew, charging them with conspiracy to violate the Anti-Kickback Statute (18 U.S.C. § 371). Concurrently, the government entered into 18-month Deferred Prosecution Agreements (DPAs) with each company. Under the DPAs, the criminal complaints remained stayed on the federal docket. Upon successful completion of all compliance obligations over the 18-month term, the criminal charges were dismissed with prejudice. Stryker entered into an 18-month Non-Prosecution Agreement (NPA), precluding the filing of formal criminal charges.

Corporate Integrity Agreements (CIAs) & Federal Monitoring

All five manufacturers entered into comprehensive 5-year Corporate Integrity Agreements (CIAs) supervised by the Office of Inspector General of the Department of Health and Human Services (HHS-OIG). The DPAs and CIAs mandated the appointment of an Independent Federal Monitor for each manufacturer, endowed with expansive authority to review corporate compliance, audit internal emails, assess ongoing physician contracts, and inspect medical education grants.

Manufacturer Entity	Civil Settlement Recovery	Criminal Disposition	Compliance Agreement	Federal Monitor Supervision
Zimmer Inc.	$169,500,000	18-Month Deferred Prosecution Agreement (Conspiracy to violate AKS)	5-Year HHS-OIG Corporate Integrity Agreement	Independent Federal Monitor appointed; comprehensive contract auditing.
DePuy Orthopaedics Inc.	$84,700,000	18-Month Deferred Prosecution Agreement (Conspiracy to violate AKS)	5-Year HHS-OIG Corporate Integrity Agreement	Independent Federal Monitor appointed; compliance protocol restructuring.
Smith & Nephew Inc.	$28,900,000	18-Month Deferred Prosecution Agreement (Conspiracy to violate AKS)	5-Year HHS-OIG Corporate Integrity Agreement	Independent Federal Monitor appointed; sales and marketing separation.
Biomet Inc.	$26,900,000	18-Month Deferred Prosecution Agreement (Conspiracy to violate AKS)	5-Year HHS-OIG Corporate Integrity Agreement	Independent Federal Monitor appointed; consulting quota reform.
Stryker Orthopaedics	$0 (No civil fine)	18-Month Non-Prosecution Agreement (Voluntary early cooperation)	5-Year HHS-OIG Corporate Integrity Agreement	Independent Federal Monitor appointed; proactive compliance program.

5. Consulting Agreements & Fair Market Value (FMV) Standards

The 2007 settlements established strict operational boundaries that redefined how orthopaedic surgeons could be engaged as commercial consultants. Previously, consulting agreements were frequently open-ended arrangements lacking rigorous deliverables, time accounting, or independent valuation.

Legitimate Clinical Consulting vs. Unlawful Inducements

Under the DPAs and modern healthcare compliance doctrine, every consulting engagement between a surgeon and an implant manufacturer must satisfy four core legal tests:

• Documented Commercial Need: The manufacturer must establish a legitimate, documented business need for the professional service prior to contracting. The contract cannot be created to “maintain goodwill” or incentivize a high-volume surgical account.
• Surgeon Qualifications: The physician consultant must possess documented surgical expertise, scientific credentials, or clinical experience directly matching the defined clinical objective.
• Tangible Deliverables: Every consulting hour billed must be supported by contemporaneous timesheets and tangible work output, such as design CAD feedback, mechanical testing evaluations, clinical protocol drafts, or peer-reviewed manuscripts.
• Decoupling from Surgical Volume: Consultant selection, contract renewal, and compensation tiers must be completely independent of the past, present, or projected surgical volume or dollar value of implants utilized by the surgeon or their healthcare facility.

Fair Market Value (FMV) Benchmarking

Compensation must represent the fair market value of the professional service in an arm’s-length transaction. Remuneration cannot reflect the financial value or volume of surgical referrals generated. Manufacturers are required to utilize independent healthcare valuation consultants to establish hourly rate schedules based on academic standing, clinical experience, specialty training, and geographic market data. Hourly rates exceeding established median benchmarks trigger mandatory internal compliance reviews and external monitor audit trails.

6. Royalties, Product Development, and Intellectual Property

Surgical innovation relies on practicing clinicians conceptualizing novel implant geometries, articulating bearing kinematics, and designing ergonomic instruments. However, royalty streams were identified by federal investigators as a significant vulnerability for disguised inducement.

Distinguishing True Innovation from Volume-Based Rewards

Prior to the settlements, certain royalty agreements compensated surgeons for minor design suggestions or granted royalties on products never patented by the physician. The 2007 DPAs and subsequent HHS-OIG guidance established rigid boundaries for royalty payments:

• True Novel Intellectual Property: Royalties may only be paid to surgeons who make meaningful, legally protectable intellectual property contributions (such as patented claims, proprietary design trade secrets, or novel mechanical utility).
• Prohibition on “Self-Usage” Royalties: A physician consultant may not receive royalty compensation on any implant or instrumentation deployed in their own surgical cases, cases performed by their practice partners, or cases within healthcare systems where they exert clinical purchasing control. Royalties must derive exclusively from arm’s-length third-party commercial sales.
• Expiration and Sunset Provisions: Royalty contracts must feature clear termination schedules aligned with patent expiration and commercial product lifecycles, preventing perpetual remuneration following minor initial involvement.

7. Institutional Value Analysis Committees & Hospital Procurement

The 2007 DOJ investigation profoundly shifted the purchasing dynamics of modern orthopaedic surgery. Historically, surgical implant selection was treated as an unassailable physician preference item (PPI), with hospitals passively paying invoices submitted by manufacturer representatives.

Transition from Surgeon Preference to Institutional Governance

Exposing the scale of financial ties between manufacturers and surgeons catalyzed hospital administrations to assume central authority over device procurement. Hospitals established formal Value Analysis Committees (VACs), comprising orthopaedic department leadership, hospital administrators, nursing leadership, biomedical engineers, and healthcare economists.

Capitated Implant Pricing and Dual-Track Vendor Negotiations

VACs introduced objective, evidence-based criteria for product adoption. Surgeons requesting new or proprietary implants must demonstrate tangible clinical efficacy, superior biomechanical survivorship, or documented health economic benefits over existing institutional formulary items. Furthermore, hospitals implemented standardized capitated pricing models, establishing fixed ceiling costs across manufacturers for primary total hip and knee constructs (femoral stems, acetabular shells, femoral components, tibial trays, and bearing inserts). This institutional purchasing governance disrupted manufacturer pricing leverage and removed economic pressure from bedside clinical selection.

8. Evolution of Professional Ethics & Societal Disclosure Standards

The regulatory scrutiny of 2007 spurred national professional organizations to fundamentally overhaul ethical codes and commercial relationships.

AAOS Standards of Professionalism on Orthopaedist-Industry Relations

In April 2007, anticipating federal findings, the American Academy of Orthopaedic Surgeons (AAOS) adopted the mandatory Standards of Professionalism on Orthopaedist-Industry Relations. The standards establish binding professional duties for all AAos fellows and members:

• Primacy of Patient Welfare: The orthopaedic surgeon’s primary clinical duty is always to the patient. Clinical judgment regarding surgical intervention, approach, and implant selection must remain uninfluenced by financial incentives or commercial considerations.
• Mandatory Disclosure: Surgeons must provide comprehensive verbal and written disclosure of financial ties, royalties, and consulting arrangements to patients, academic institutions, conference attendees, and medical journal editors.
• Separation of Education and Marketing: Commercial exhibits and promotional marketing at scientific meetings must remain physically and programmatically segregated from peer-reviewed continuing medical education (CME).
• Prohibition on Commercial Gifts: Accepting recreational gifts, entertainment, sporting event tickets, or luxury travel from device manufacturers is classified as an explicit professional violation.

9. Downstream Legislative Impact: The Physician Payments Sunshine Act & CMS Open Payments

The most enduring systemic consequence of the 2007 DOJ investigation was the legislative enactment of statutory transparency at the federal level.

Section 6002 of the Affordable Care Act

Inspired by the public disclosure registries mandated under the 2007 DPAs, United States Senators Chuck Grassley and Herb Kohl introduced the Physician Payments Sunshine Act. In 2010, the legislation was enacted into federal law as Section 6002 of the Patient Protection and Affordable Care Act (PPACA; 42 U.S.C. § 1320a-7h). The law created the Centers for Medicare & Medicaid Services (CMS) Open Payments Program.

Categories of Reportable Payments

Under Open Payments regulations, all applicable medical device, biologic, and pharmaceutical manufacturers operating in the United States are legally required to report annually all financial transfers of value ($10 or greater, or cumulative annual transfers exceeding $100) made to licensed physicians and teaching hospitals. Reportable categories are publicly cataloged into distinct statutory classes:

• General Payments: Consulting fees, compensation for non-consulting services (such as faculty lecturing), honoraria, food and beverage, gifts, travel, lodging, and entertainment.
• Research Payments: Direct research grants, investigator-sponsored studies, clinical trial support, and pre-clinical laboratory testing.
• Ownership & Investment Interests: Stock options, partnership shares, equity, debt instruments, and proprietary licensing rights held by physicians or their immediate family members.
• Royalties and Licenses: Direct payments resulting from intellectual property licensing, design patents, and technology transfers.

10. Patient Perceptions & The Doctor-Patient Relationship

Public exposure of surgeon-industry financial relationships raised significant ethical questions regarding the impact of financial disclosure on patient autonomy, trust, and informed consent.

Patient Understanding of Industry Ties

Peer-reviewed investigation into patient attitudes reveals a nuanced clinical reality. While prospective surveys confirm that over 70% of surgical patients consider surgeon disclosure of manufacturer financial relationships essential, more than 60% of patients fail to distinguish between different types of compensation (e.g., confusing royalties earned for patented engineering breakthroughs with promotional marketing consulting). Patients consistently express high comfort and trust when royalties reflect genuine technical innovation that advances surgical safety, but express heightened concern regarding general consulting fees or volume-driven incentives.

Preserving Trust Through Transparent Clinical Communication

Data demonstrates that transparent, proactive disclosure by the attending surgeon during the preoperative informed consent process does not diminish patient trust. Patients appreciate forthright communication explaining why a specific implant was selected based on clinical anatomy, survivorship data, and bone stock requirements, alongside full transparency regarding the surgeon’s developmental involvement.

11. Compliance Pearls and Legal Pitfalls

Operating safely within modern orthopaedic practice requires clinical excellence and compliance vigilance. Practicing surgeons must adhere to structured operational principles:

Essential Compliance Pearls

• Insist on Written, Executed Agreements in Advance: Never perform consulting, clinical advisory, or educational services without a fully executed, formal written contract specifying the scope of work, defined business need, hourly rate, and maximum billable hours.
• Maintain Contemporaneous Time Records: Document every consulting hour at the time services are performed. Maintain detailed records detailing the specific clinical challenge addressed, CAD files reviewed, or educational materials authored.
• Ensure Institutional Review & Employer Approval: In academic medical centers and employed healthcare systems, obtain formal approval from the institutional conflict of interest committee or legal compliance office prior to executing industry agreements.
• Proactively Disclose Across All Professional Venues: Maintain a living, verified record of all financial ties. Ensure complete concordance across hospital credentialing files, journal submission forms, scientific podium presentations, and Open Payments records.

Critical Legal & Contractual Pitfalls

• Accepting Compensation for Routine Clinical Data Collection: Do not accept industry “registry” or “post-market surveillance” payments that lack formal Institutional Review Board (IRB) approval, valid scientific protocols, or substantial documentation requirements.
• Participating in “Advisory Boards” Lacking Rigorous Deliverables: Beware of weekend advisory panels hosted at resort destinations where substantive technical input is minimal and the primary agenda is commercial networking.
• Receiving Royalties on Personal Surgical Cases: Never accept royalty distributions on implants or instruments deployed in your own operating rooms or within your direct healthcare organization.
• Tying Academic Research Grants to Commercial Utilization: Industry funding for investigator-initiated research must be managed through arm’s-length institutional research grants, never through discretionary personal accounts linked to surgical volume.

12. Contemporary Controversies & Emerging Frontiers

While the 2007 DOJ settlements established the foundation for modern compliance, the orthopaedic landscape continues to face evolving regulatory challenges.

Physician-Owned Distributorships (PODs)

Following the 2007 settlements, certain surgeons and device intermediaries established Physician-Owned Distributorships (PODs), particularly in spine surgery and orthopaedic trauma. In a POD model, operating surgeons hold equity ownership in an entity that purchases surgical hardware from manufacturers and resells it to the hospitals where those same surgeons operate. In 2013, the HHS-OIG issued a Special Fraud Alert identifying PODs as inherently suspect under the Anti-Kickback Statute, citing evidence that PODs incentivize unnecessary surgeries, increased implant complexity, and improper financial inducement. Federal enforcement against POD arrangements remains an active DOJ priority.

Digital Health, Robotics, and Artificial Intelligence Consulting

The contemporary expansion of computer-assisted surgery, robotic arm arthroplasty platforms, and patient-specific artificial intelligence planning software has created new consulting paradigms. Surgeons are increasingly engaged to provide proprietary anatomical datasets, train deep learning algorithms, and validate surgical robotic planning workflows. Establishing fair market value for algorithmic data training and software validation presents novel valuation complexities requiring careful compliance oversight.

Open Payments Data Discordance

Investigations analyzing concordance between self-reported journal disclosures and CMS Open Payments data continue to identify discrepancies. Surgeons frequently cite ambiguities in manufacturer reporting categories, incorrect attribution of research grants, and administrative friction in disputing inaccurate Open Payments entries. Continued efforts toward automated, unified disclosure platforms remain essential to maintain complete professional transparency.

13. Evidence-Based Synthesis

Modern clinical decision-making is grounded in high-quality randomized controlled trials and prospective registry analyses, corroborated by seminal biomechanical and anatomical descriptions.

Clinical Question / Investigation	Level of Evidence	Pivotal Landmark Study	Study Design & Methodology	Cohort Size / Follow-up	Primary Outcome / Effect Size	DOI
What were the legal foundations, settlement terms, and compliance mandates of the 2007 DOJ investigation into major orthopaedic implant manufacturers?	Level IV	Healy WL, Peterson RN (2009)	Health Policy & Legal Regulatory Analysis	5 major joint reconstruction manufacturers (Zimmer, DePuy, Biomet, Smith & Nephew, Stryker) representing ~95% of the US hip and knee market	4 manufacturers entered into 18-month Deferred Prosecution Agreements (DPAs) and 5-year Corporate Integrity Agreements (CIAs), paying $311 million in civil settlements; Stryker entered a non-prosecution agreement. Mandated public web disclosure of consulting payments, fair market value (FMV) standards, and independent federal compliance monitoring.	DOI
How well do orthopaedic surgery patients understand financial disclosures and what is the impact of surgeon-industry relationships on patient trust?	Level IV	Lieberman JR, Pensak MJ, Kelleher MS et al (2013)	Prospective Cross-Sectional Survey Study	200 consecutive adult orthopaedic patients presenting for total joint arthroplasty	While 71% of patients believed disclosure of industry relationships was essential, over 60% did not fully comprehend the distinction between consulting fees, royalties, and research support. Transparent disclosure did not reduce patient trust in their attending surgeon.	DOI
What is the degree of concordance between self-reported author conflict of interest disclosures in orthopaedic literature and federal Open Payments data?	Level IV	Janney CF, Shazadeh Safavi K, Schneider GJ et al (2019)	Retrospective Concordance & Database Registry Analysis	812 orthopaedic physician authors publishing across landmark journals	Substantial discordance was observed between self-reported journal disclosures and Open Payments records, demonstrating systemic underreporting of general consulting payments and underscoring the necessity for automated verification systems.	DOI
What are patient attitudes toward surgeon royalties, consulting contracts, and device development partnerships in joint arthroplasty?	Level IV	Camp MW, Mattingly DA, Gross AE et al (2013)	Multicenter Cross-Sectional Survey Study	377 adult orthopaedic patients across academic medical centers	Patients demonstrated broad acceptance and appreciation for royalties linked to genuine patented device innovation (72%), but expressed skepticism regarding general marketing consulting fees (48%), supporting distinct ethical boundaries between invention and promotion.	DOI
Are orthopaedic surgeons cognizant of the true institutional purchase costs of the implants and instruments they utilize?	Level II	Streit JJ, Youssef A, Coale RM et al (2013)	Comparative Cross-Sectional Evaluation	103 orthopaedic attending surgeons and resident trainees across multiple subspecialties	Only 19% of surgeons accurately estimated implant costs within 20% of true cost; surgeons consistently underestimated implant expenses, demonstrating an educational disconnect between implant selection and healthcare expenditure.	DOI

14. References

• Healy WL, Peterson RN. Department of Justice investigation of orthopaedic industry. J Bone Joint Surg Am. 2009. doi:10.2106/JBJS.I.00096 [Level IV: Health Policy & Legal Regulatory Analysis]
• Lieberman JR, Pensak MJ, Kelleher MS et al. Disclosure of financial conflicts of interest: an evaluation of orthopaedic surgery patients’ understanding. Clin Orthop Relat Res. 2013. doi:10.1007/s11999-012-2525-y [Level IV: Prospective Cross-Sectional Survey Study]
• Janney CF, Shazadeh Safavi K, Schneider GJ et al. Disclosures Undisclosed. J Bone Joint Surg Am. 2019. doi:10.2106/JBJS.18.01061 [Level IV: Retrospective Concordance & Database Registry Analysis]
• Camp MW, Mattingly DA, Gross AE et al. Patients’ views on surgeons’ financial conflicts of interest. J Bone Joint Surg Am. 2013. doi:10.2106/JBJS.L.00270 [Level IV: Multicenter Cross-Sectional Survey Study]
• Streit JJ, Youssef A, Coale RM et al. Orthopaedic surgeons frequently underestimate the cost of orthopaedic implants. Clin Orthop Relat Res. 2013. doi:10.1007/s11999-012-2757-x [Level II: Comparative Cross-Sectional Evaluation]

15. Master Class Pro-Tip

True surgical innovation and collaborative device development are indispensable to advancing patient care, but they require uncompromising ethical boundaries. To ensure complete compliance and maintain public trust, adhere to the ‘Front Page of the Newspaper’ standard: never enter into any consulting contract, advisory board, or royalty arrangement that you would not feel entirely proud to see published on the front page of the morning newspaper or disclosed directly to your next clinic patient. Keep meticulous, contemporaneous time logs of all consulting deliverables, ensure institutional conflict of interest approval before signing, strictly exclude royalties on personal cases, and let your implant selection be governed solely by anatomical appropriateness and proven clinical survivorship.

Master Class Practice Pearl: Healthcare Compliance & Consulting Ethics